By Christine Van Dusen
Atlanta, Nov. 30 - Chile's CFR Pharmaceuticals SA sold $300 million 10-year notes (/BB+/BBB-) at par to yield 5 1/8%, a market source said.
Deutsche Bank and JPMorgan were the bookrunners for the Rule 144A and Regulation S deal.
The notes include a change-of-control put at 101% and a make-whole call at Treasuries plus 50 basis points.
Proceeds will be used to fund acquisitions and for general corporate purposes.
CFR is a pharmaceutical company based in Santiago, Chile.
| Issuer: | CFR Pharmaceuticals SA
|
| Amount: | $300 million
|
| Maturity: | Dec. 6, 2022
|
| Description: | Senior notes
|
| Bookrunners: | Deutsche Bank, JPMorgan
|
| Coupon: | 5 1/8%
|
| Price: | Par
|
| Yield: | 5 1/8%
|
| Call options: | Make-whole call at Treasuries plus 50 bps
|
| Change-of-control put: | At 101%
|
| Trade date: | Nov. 29
|
| Settlement date: | Dec. 6
|
| Ratings: | Standard & Poor's: BB+
|
| Fitch: BBB-
|
| Distribution: | Rule 144A and Regulation S
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
